AbbVie (NYSE:ABBV) Stock Price Down 1.2% - What's Next?

Key Points

• Shares dipped about 1.2% to roughly $202, trading below the 50- and 200-day moving averages on below-average volume, and a high trailing P/E (~99.8) presents near-term technical and valuation headwinds.
• AbbVie beat Q1 estimates with ~$15.0B revenue and $2.65 EPS (vs. $2.59 consensus), with 12.4% year-over-year revenue growth and product/pipeline gains (SKYRIZI momentum and a Phase 1a readout for ABBV‑142) supporting diversification beyond Humira.
• The stock retains its income appeal as a Dividend King (quarterly dividend $1.73, ~3.4% yield), while analysts hold a "Moderate Buy" consensus with an average price target near $252.90.

AbbVie Inc. (NYSE:ABBV - Get Free Report) shares fell 1.2% on Thursday . The company traded as low as $202.03 and last traded at $202.59. 6,342,964 shares changed hands during mid-day trading, a decline of 11% from the average session volume of 7,160,306 shares. The stock had previously closed at $205.03.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 results beat expectations: AbbVie reported stronger-than-expected Q1 revenue (~$15.0B) and an EPS beat (reported $2.65 vs. ~$2.59 consensus), and commentary highlighted growth beyond Humira — bolstering the long-term dividend-king thesis. AbbVie Delivers Strong Q1 Earnings Beyond Humira
• Positive Sentiment: Pipeline safety milestone: AbbVie completed a Phase 1a safety study for ABBV‑142, a clinical-stage asset — a low-risk early readout that nudges pipeline value and could support longer-term upside if follow-ups are positive. AbbVie Completes Early Safety Study for ABBV-142
• Positive Sentiment: SKYRIZI momentum strengthens the growth case: recent formulary wins, reimbursement progress in ulcerative colitis and broader label/clinical updates for SKYRIZI (and continued RINVOQ progress) reinforce revenue diversification away from Humira. Does Strong Q1 Results And SKYRIZI Expansion Reshape The Bull Case For AbbVie (ABBV)?
• Neutral Sentiment: Investor access ahead: AbbVie will present at the Bank of America Healthcare Conference (May 13), providing an opportunity for management to update guidance, pipeline timing and commercial cadence — a potential catalyst depending on commentary. AbbVie to Present at the Bank of America Securities Healthcare Conference
• Neutral Sentiment: Industry and analyst focus: post‑earnings analyst questions and DDW conference readouts are keeping attention on trial endpoints and competitive positioning — useful for longer-term modelling but not immediate earnings surprises. 5 must-read analyst questions from AbbVie’s Q1 earnings call DDW 2026: key readouts from the conference
• Neutral Sentiment: Competitive signals: Avalo’s Phase 2 skin-disease win has drawn attention from larger players and could influence M&A or partnership dynamics in dermatology — a watch item for AbbVie but not an immediate balance-sheet event. Avalo’s phase 2 skin disease win fuels pursuit of AbbVie despite placebo headwind
• Positive Sentiment: Dividend appeal remains intact: coverage in income-focused publications highlights AbbVie’s status as a Dividend King, supporting buy-and-hold demand from income investors. 6 Pharma Dividend Stocks Yielding Up to 6.44% Want Reliable Dividend Income in May? These 2 Stocks Deliver
• Negative Sentiment: Valuation and technicals are headwinds: ABBV trades below its 50‑ and 200‑day moving averages and shows a high trailing P/E (~99.8), which can prompt profit‑taking and reduce near-term upside despite operational positives.

Analyst Ratings Changes

Several research firms recently weighed in on ABBV. Piper Sandler dropped their price target on AbbVie from $299.00 to $294.00 and set an "overweight" rating on the stock in a research report on Thursday, April 23rd. Berenberg Bank set a $275.00 target price on shares of AbbVie in a research report on Tuesday, January 20th. DZ Bank raised AbbVie from a "hold" rating to a "strong-buy" rating in a research report on Thursday, April 30th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $240.00 price target on shares of AbbVie in a research note on Thursday, April 30th. Finally, Guggenheim reiterated a "buy" rating and issued a $249.00 target price on shares of AbbVie in a research note on Friday, May 1st. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $252.90.

AbbVie Stock Performance

The company has a market capitalization of $358.21 billion, a P/E ratio of 99.80, a P/E/G ratio of 0.71 and a beta of 0.32. The company has a 50-day simple moving average of $213.69 and a 200 day simple moving average of $221.19.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 911.57%. The business had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. During the same quarter last year, the company posted $2.46 earnings per share. AbbVie's quarterly revenue was up 12.4% on a year-over-year basis. As a group, sell-side analysts forecast that AbbVie Inc. will post 14.3 earnings per share for the current year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.4%. The ex-dividend date is Wednesday, April 15th. AbbVie's payout ratio is currently 340.89%.

Insiders Place Their Bets

In related news, SVP David Ryan Purdue sold 5,230 shares of the firm's stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president directly owned 2,654 shares of the company's stock, valued at $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.06% of the company's stock.

Hedge Funds Weigh In On AbbVie

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ABBV. Brighton Jones LLC grew its holdings in AbbVie by 17.4% during the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company's stock worth $4,072,000 after acquiring an additional 3,401 shares during the last quarter. Revolve Wealth Partners LLC grew its holdings in AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company's stock worth $1,294,000 after acquiring an additional 3,064 shares during the period. Schnieders Capital Management LLC. grew its stake in shares of AbbVie by 5.0% during the second quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company's stock worth $3,056,000 after purchasing an additional 789 shares during the period. Ieq Capital LLC boosted its holdings in AbbVie by 4.6% during the second quarter. Ieq Capital LLC now owns 120,035 shares of the company's stock worth $22,281,000 after buying an additional 5,274 shares during the last quarter. Finally, Worldquant Millennium Advisors LLC boosted its stake in AbbVie by 117.3% during the 2nd quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company's stock worth $210,685,000 after acquiring an additional 612,702 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.